Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Valbiotis

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes
From Valbiotis
Via Business Wire
Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap
From Valbiotis
Via Business Wire
Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science
From Valbiotis
Via Business Wire
Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar
From Valbiotis
Via Business Wire
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure
From Valbiotis
Via Business Wire
Valbiotis Announces Its Roadmap for 2023: a Pivotal Year in the Execution of Its Clinical, Industrial and Commercial Strategy
From Valbiotis
Via Business Wire
Valbiotis Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University
From Valbiotis
Via Business Wire
Valbiotis Will Present Significant Preclinical Results for Its Active Substance TOTUM•448 Against Fatty Liver Diseases (NAFL and NASH), at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
From Valbiotis
Via Business Wire
Valbiotis Accelerates Its Marketing Strategy
From Valbiotis
Via Business Wire
Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia
From Valbiotis
Via Business Wire
Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022
From Valbiotis
Via Business Wire
Frédéric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors
From Valbiotis
Via Business Wire
Valbiotis Announces Completion of Recruitment for the Phase II/III REVERSE-IT Clinical Study With TOTUM•63 Against Prediabetes, in Partnership With Nestlé Health Science
From Valbiotis
Via Business Wire
Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor
From Valbiotis
Via Business Wire
Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Conducted by the INAF1, in Partnership With Nestlé Health Science
From Valbiotis
Via Business Wire
Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia
From Valbiotis
Via Business Wire
Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard
From Valbiotis
Via Business Wire
Valbiotis Publishes Its 2021 Annual Report
From Valbiotis
Via Business Wire
Valbiotis Presents Its 2022 Financial Communication Calendar
From Valbiotis
Via Business Wire
Valbiotis Announces Approval to Launch the Two Phase II/III INSIGHT and INSIGHT 2 Clinical Studies, the Last Step in the Development of TOTUM•854 For the Reduction of Blood Pressure
From Valbiotis
Via Business Wire
Valbiotis - Increased Momentum in the Clinical Newsflow for Major Indications: Results Expected in 2022 for Prediabetes, Hypercholesterolemia and High Blood Pressure
From Valbiotis
Via Business Wire
Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
From Valbiotis
Via Business Wire
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting
From Valbiotis
Via Business Wire
Valbiotis Reviews Its Activities and Publishes Its Financial Report for the First Half of 2021
From Valbiotis
Via Business Wire
Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER
From Valbiotis
Via Business Wire
Valbiotis Releases its Letter to Shareholders for 2021
From Valbiotis
Via Business Wire
Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease
From Valbiotis
Via Business Wire
Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action Clinical Study by INAF1 at Laval University in Quebec City, in Partnership With Nestlé Health Science
From Valbiotis
Via Business Wire
Valbiotis Appoints Sébastien Bessy, International Expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer
From Valbiotis
Via Business Wire
Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action
From Valbiotis
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.